ClinicalTrials.gg
CompletedNCT04181788Updated Jun 15, 2026Results posted

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

A Phase 1/2 interventional study of PF-06801591 in Advanced Malignancies and Non-small-cell Lung Cancer, sponsored by Pfizer. Completed at 49 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.

Enrollment
45th of 136
155 · median 79
Started
2020
with 13 others
Phase 1/2
13 of 158
1 open now
Registered
94th of 158
by date

Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 45th largest by enrollment of the 136 interventional ones that give a count, is one of 14 that started in 2020, is one of 13 in phase 1/2, and was the 94th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, or all of them as a file.
02

Study summary

This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.

This study consists of 2 parts:

Phase 1b part (dose escalation and dose expansion) in patients with advanced malignancies in Asia and a global Phase 2 part in non small cell lung cancer (NSCLC) patients.

03

Conditions studied

  • Advanced Malignancies
  • Non-small-cell Lung Cancer

Keywords

  • Advanced solid tumors
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years (≥ 20 years in Japan; ≥ 19 years in South Korea)
  • Easter Cooperative Oncology Group () performance status 0 or 1
  • Adequate bone marrow function, renal and liver functions Phase 1b
  • Histological or Cytological diagnosis of advanced solid tumor with clinical evidence of response to or PD-L1 agent
  • Participant must have received at least 1 for recurrent or disease, and must have progressed/, be refractory, or intolerant to standard therapy approved for the specific tumor type Phase 2
  • Participants must have a documented diagnosis of stage III where participants are not candidates for surgical resection or definitive chemoradiation, or stage IV NSCLC
  • EGFR mutation, BRAF mutation, and ALK or ROS1 translocation/rearrangement are not permitted
  • Participants whose tumor is known to be PD-L1 positive (Tumor Proportion Score [TPS] ≥1%) or unknown are eligible
  • Up to 1 line of prior therapy in advanced or metastatic disease settings allowed
  • Participant should not have received prior treatment with anti PD-1/PD-L1 drugs
  • At least one as defined by version 1.1

Exclusion criteria

Exclusion Criteria:

  • Participants with known symptomatic requiring
  • Participants with Interstitial Lung Disease history or complication
  • Q-T interval corrected for heart rate > 450 msec for male participants or QTc > 470 msec for female participants or QTc > 480 msec in participants with right bundle branch block.
  • Hypertension that cannot be controlled by medications (eg, systolic > 150 mmHg and diastolic > 90 mmHg) despite optimal medical therapy.
  • Known or suspected to active ingredient or of the study drug.
  • History of Grade ≥3 immune mediated AE (including / ALT elevations that where considered drug related and cytokine release syndrome [CRS]) that was considered related to prior immune modulatory therapy (eg, , co-stimulatory agents, etc.) and required therapy (For Phase 1b only).
  • Vaccination with within 4 weeks prior to randomization is prohibited; however inactivated vaccines are permitted.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Arm A1 (Phase 1b)

    Drug: PF-06801591

  • Experimental
    Arm B1 (Phase 1b)

    Drug: PF-06801591

  • Experimental
    Arm A2 (Phase 2)

    Drug: PF-06801591

  • Experimental
    Arm B2 (Phase 2)

    Drug: PF-06801591

Interventions

  • A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PDL1/ PD-L2.

06

What researchers measure

Primary outcomes

  1. Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2). For the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.

    Time frame: Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms

  2. Phase 2: AUCτ of PF-06801591 at Steady State

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

    Time frame: Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm

  3. Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)

    Time frame: Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

    Time frame: Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).

  2. Number of Participants With Laboratory Abnormalities

    Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.

    Time frame: Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).

  3. Pharmacokinetic Parameters: AUCτ After First Dose

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

    Time frame: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1

  4. Pharmacokinetic Parameters: Ctrough After First Dose

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Ctrough is pre-dose concentration after single dose (first dose).

    Time frame: Phase 1b/2: Cycle 2 Day 1 for all Arms

  5. Pharmacokinetic Parameters: Ctrough at Steady State

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)

    Time frame: Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3

  6. Number of Participants With Treatment-Induced Anti-Drug Antibody (ADA) /Neutralizing Antibodies (NAb)

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Treatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09). Treatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.

    Time frame: Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms

  7. Number of Participants With Objective Response (OR)

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1. Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

    Time frame: Phase 1b/2: Up to 30 months

  8. Time to Response (TTR)

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). TTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.

    Time frame: Phase 1b/2: Up to 30 months

  9. Number of Participants With Objective Response (Complete Response + Partial Response) Reported by Baseline Programmed Death-Ligand 1 (PD-L1) Status (High, Low, and Unknown)

    This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.

    Time frame: Phase 1b/2: Baseline up to 30 months

07

Results

Posted May 8, 2023

Participant flow

TREATMENT
Participant flow — TREATMENT
MilestonePhase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
Started4126124180
Completed000000
Not completed4126124180
Withdrew: Adverse event021013
Withdrew: Death000088
Withdrew: Physician decision000001
Withdrew: Progressive disease33572038
Withdrew: Global deterioration of health status020028
Withdrew: Withdrawal by subject120035
Withdrew: Other unspecified000002
Withdrew: Ongoing0305715
FOLLOW-UP
Participant flow — FOLLOW-UP
MilestonePhase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
Started39672049
Completed3842922
Not completed01251127
Withdrew: Death0012820
Withdrew: Lost to follow-up000002
Withdrew: Withdrawal by subject000010
Withdrew: Other unspecified010003
Withdrew: Ongoing001322

Outcome measures

PrimaryPhase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with first line (1L) and second line (2L) non-small cell lung cancer (NSCLC) (Phase 2). For the Phase 1b, any of the following AEs occurring during the DLT observation period (the first cycle of treatment) which were attributable to the investigational product were classified as DLTs: Grade 5 AE not clearly due to the underlying disease or extraneous causes; Hematologic toxicity; Non-Hematologic Toxicity; Delay of ≥ 3 weeks in receiving the next scheduled administration due to persisting treatment-related toxicities.

Time frame:
Phase 1b: at the end of cycle 1 (28 days) for the PF-06801591 300 mg SC Q4W arms, and (42 days) for the PF-06801591 600 mg SC Q6W arms
Reported as:
Count of participants · Participants
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)
ParticipantsPhase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6W
Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT)0000
PrimaryPhase 2: AUCτ of PF-06801591 at Steady State

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (at steady state, starting at Week 12). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

Time frame:
Phase 2: Cycle 4 Day 1, 8, 15, 22 and Cycle 5 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1, 8, 15, 29 and Cycle 4 Day 1 for the PF-06801591 600 mg SC Q6W arm
Reported as:
Geometric mean · microgram*hour per milliliter (μg*hr/mL)
Phase 2: AUCτ of PF-06801591 at Steady State
microgram*hour per milliliter (μg*hr/mL)Phase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
Phase 2: AUCτ of PF-06801591 at Steady State20800 ± 5448090 ± 47
Statistical analysis
  • Phase 2 300 mg SC Q4W vs Phase 2 600 mg SC Q6W · Ratio of experimental vs control: 231.20 · 90% CI 190.09 to 281.21
PrimaryPhase 2: Ctrough of PF-06801591 at Steady State, at Week 12

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)

Time frame:
Phase 2: Cycle 4 Day 1 for the PF-06801591 300 mg SC Q4W arm, and Cycle 3 Day 1 for the PF-06801591 600 mg SC Q6W arm
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
Phase 2: Ctrough of PF-06801591 at Steady State, at Week 12
microgram per milliliter (μg/mL)Phase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
Phase 2: Ctrough of PF-06801591 at Steady State, at Week 1221.48 ± 6023.95 ± 74
Statistical analysis
  • Phase 2 300 mg SC Q4W vs Phase 2 600 mg SC Q6W · Ratio of experimental vs control: 111.48 · 90% CI 86.31 to 143.99
SecondaryNumber of Participants With Treatment-Emergent Adverse Events

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.

Time frame:
Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).

Results for this outcome have not been posted.

SecondaryNumber of Participants With Laboratory Abnormalities

Laboratory results were classified according to the NCI-CTCAE criteria version 5.0. Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care (ADL); Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. Number of participants with Grade 1 to Grade 4 laboratory abnormalities were reported.

Time frame:
Phase 1b/2: On-treatment period is defined as the time from the first dose of study treatment through minimum (30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day).

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameters: AUCτ After First Dose

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). AUCτ is area under the plasma concentration-time profile from time zero to the next dose (after single dose). (τ = X days, where X = 28 days for Q4W regimen and 42 days for Q6W regimen)

Time frame:
Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Cycle 1 Day 1, 8, 15, 22, Cycle 2 Day 1; for the PF-06801591 600 mg SC Q6W arms, Cycle 1 Day 1, 8, 15, 29, Cycle 2 Day 1

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameters: Ctrough After First Dose

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Ctrough is pre-dose concentration after single dose (first dose).

Time frame:
Phase 1b/2: Cycle 2 Day 1 for all Arms

Results for this outcome have not been posted.

SecondaryPharmacokinetic Parameters: Ctrough at Steady State

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Steady state Ctrough is pre-dose concentration following multiple dosing at steady state (Week 12)

Time frame:
Phase 1b/2: For the PF-06801591 300 mg SC Q4W arms, Day 1 of Cycle 4; for the PF-06801591 600 mg SC Q6W arms, Day 1 of Cycle 3

Results for this outcome have not been posted.

SecondaryNumber of Participants With Treatment-Induced Anti-Drug Antibody (ADA) /Neutralizing Antibodies (NAb)

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). Treatment-induced ADA = Baseline ADA titer was missing or negative and participant had ≥1 post-treatment positive ADA titer (ADA titer greater than or equal to 99 with assay cut-point of 1.09). Treatment-induced NAb = Baseline NAb titer was missing or negative or ADA-negative and participant had ≥1 post-treatment positive NAb titer.

Time frame:
Phase 1b/2: Day 1 of Cycle 1, 2, 3, 4, 6, 8, 10 and end of treatment (EOT) for the PF-06801591 300 mg SC Q4W arms; Day 1 of Cycle 1, 2, 3, 4, 5, 7 and EOT for the PF-06801591 600 mg SC Q6W arms

Results for this outcome have not been posted.

SecondaryNumber of Participants With Objective Response (OR)

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed best overall response (BOR) of complete response (CR) or partial response (PR) according to RECIST v1.1. Complete Response (CR): Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. Partial Response (PR): Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed.

Time frame:
Phase 1b/2: Up to 30 months

Results for this outcome have not been posted.

SecondaryTime to Response (TTR)

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). TTR was defined for participants with confirmed objective response (CR or PR) as the time from the 'start date' to the date of first documentation of objective tumor response which is subsequently confirmed.

Time frame:
Phase 1b/2: Up to 30 months

Results for this outcome have not been posted.

SecondaryNumber of Participants With Objective Response (Complete Response + Partial Response) Reported by Baseline Programmed Death-Ligand 1 (PD-L1) Status (High, Low, and Unknown)

This study included Asian participants with advanced solid tumors (Phase 1b) and global participants with 1L and 2L NSCLC (Phase 2). OR was defined as confirmed BOR of CR or PR according to RECIST v1.1. CR: Complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). All target lesions must be assessed. PR: Greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. All target lesions must be assessed. PD-L1 expression was defined as the number of PD-L1 positive cells and/or qualitative assessment of PD-L1 staining on tumor and inflammatory cells in regions of interest that are defined by tumor cell morphology.

Time frame:
Phase 1b/2: Baseline up to 30 months

Results for this outcome have not been posted.

Adverse events

Collected over Phase 1b/2: On-treatment period (defined as the time from the first dose of study treatment through minimum [30 days + last dose of study treatment, start day of new anti-cancer drug therapy - 1 day] for the treatment-emergent adverse events (TEAEs); Baseline up to 30 months for all-causality mortality.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1b Escalation 300 mg SC Q4W0/4 (0%)1/4 (25%)4/4 (100%)
Phase 1b Expansion 300 mg SC Q4W0/12 (0%)2/12 (16.7%)11/12 (91.7%)
Phase 1b Escalation 600 mg SC Q6W1/6 (16.7%)0/6 (0%)6/6 (100%)
Phase 1b Expansion 600 mg SC Q6W2/12 (16.7%)0/12 (0%)12/12 (100%)
Phase 2 300 mg SC Q4W16/41 (39%)16/41 (39%)40/41 (97.6%)
Phase 2 600 mg SC Q6W31/80 (38.8%)13/80 (16.3%)58/80 (72.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPhase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
Tubulointerstitial nephritisRenal and urinary disorders1/40/120/60/120/410/80
Disease progressionGeneral disorders0/40/120/60/124/412/80
VertigoEar and labyrinth disorders0/41/120/60/120/410/80
Pancreatitis acuteGastrointestinal disorders0/41/120/60/120/410/80
PneumoniaInfections and infestations0/41/120/60/122/412/80
MyalgiaMusculoskeletal and connective tissue disorders0/41/120/60/120/410/80
AnaemiaBlood and lymphatic system disorders0/40/120/60/122/410/80
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/40/120/60/122/410/80
COVID-19 pneumoniaInfections and infestations0/40/120/60/120/412/80
Ventricular extrasystolesCardiac disorders0/40/120/60/121/410/80
Most frequent other events
Showing 10 of 112
Most frequent other events
EventPhase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6W
AnaemiaBlood and lymphatic system disorders1/44/120/66/128/4110/80
PruritusSkin and subcutaneous tissue disorders1/43/123/62/121/416/80
Blood glucose increasedInvestigations0/40/120/64/120/410/80
HypertriglyceridaemiaMetabolism and nutrition disorders0/44/120/62/120/410/80
HypoalbuminaemiaMetabolism and nutrition disorders0/44/120/63/122/412/80
HypokalaemiaMetabolism and nutrition disorders0/44/120/62/120/411/80
HyperthyroidismEndocrine disorders1/40/120/60/121/410/80
HypothyroidismEndocrine disorders1/40/121/60/121/415/80
DiarrhoeaGastrointestinal disorders1/40/120/60/123/411/80
ToothacheGastrointestinal disorders1/40/120/60/120/410/80

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Phase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6WTotal
Mean62.0 ± 13.2957.3 ± 15.7862.7 ± 10.3362.4 ± 10.0263.9 ± 11.7562.9 ± 10.6262.6 ± 11.33
Age, Customized
Age, Customized(Participants)Phase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6WTotal
<65 years2746184885
65 - <75 years1514172149
75 - <85 years101251019
≥85 years0000112
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6WTotal
Female463391439
Male06393266116
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6WTotal
Hispanic or Latino0000000
Not Hispanic or Latino4126124180155
Unknown or Not Reported0000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1b Escalation 300 mg SC Q4WPhase 1b Expansion 300 mg SC Q4WPhase 1b Escalation 600 mg SC Q6WPhase 1b Expansion 600 mg SC Q6WPhase 2 300 mg SC Q4WPhase 2 600 mg SC Q6WTotal
White0000346296
Black or African American0000000
Asian41261271859
Multiracial0000000
Not Reported0000000
08

Study locations

49 sites
  • Beijing Cancer hospital
    Beijing, Beijing Municipality 100142, China
  • Chongqing Cancer Hospital
    Chongqing, Chongqing Municipality 400030, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 201107, China
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Russian Research Centre for Radiology and Surgical Technologies
    Saint Petersburg, Pesochny 197758, Russia
  • Private Medical Institution "Euromedservice"
    Pushkin, Sankt-Peterburg 196603, Russia
  • Klinika UZI 4D, LLC
    Pyatigorsk, Stavropol Kray 357502, Russia
  • State budgetary institution of healthcare of Yaroslavl region "Clinical oncology hospital"
    Yaroslavl, Yaroslavl Oblast 150054, Russia
  • Evimed Llc
    Chelyabinsk, 454048, Russia
  • Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine
    Chelyabinsk, 454087, Russia
  • Ars Medika Center, LLC
    Kaliningrad, 236006, Russia
  • GBUZ Regional Clinical Hospital of Kaliningrad region
    Kaliningrad, 236016, Russia
  • Enlimed Llc
    Kopeysk, 456620, Russia
  • Orenburg Regional Clinical Oncological Dispensary
    Orenburg, 460021, Russia
  • Russian Scientific Center For Radiology and Surgical Technologies
    Pesochny, 197758, Russia
  • LLC Medical Center "Magnit"
    Saint Petersburg, 190005, Russia
  • Llc "Mss"
    Saint Petersburg, 191025, Russia
  • North-West Medical Center
    Saint Petersburg, 191119, Russia
  • Road clinical clinic of JSC "RZD"
    Saint Petersburg, 192007, Russia
  • NS HI "Road Clinical Hospital of JSC "Russian Railways""
    Saint Petersburg, 195271, Russia
  • Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg
    Saint Petersburg, 195271, Russia
  • LLC "Diagnostic center "Energo"
    Saint Petersburg, 196247, Russia
  • Medical University REAVIZ
    Samara, 443001, Russia
  • Medical University REAVIZ
    Samara, 443011, Russia
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21656, South Korea
  • Severance Hospital, Yonsei Univ. Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Limited Liability Company "MedX-ray International Group"
    Pliuty Village, Kyiv Oblast, Ukraine
  • Asklepion Medical Center
    Khodosovka, Kyivska Oblast 08173, Ukraine
  • "Medeya Sumy" LLC
    Sumy, Sumska Oblast 40021, Ukraine
  • Communal Non-profit Enterprise City Clinical Hospital #4 of Dnipro City Council
    Dnipro, 49102, Ukraine
  • LLC "AR DI PI Ukraine"
    Dnipro, 49102, Ukraine
  • Llc "Mdc Expert"
    Dnipro, 49102, Ukraine
  • Municipal Non-profit Enterprise "SubCarpathian Clinical Oncological Centre of Ivano-Frankivsk RC"
    Ivano-Frankivsk, 76018, Ukraine
  • Private Enterprise of Private Manufacturing Company "Acinus", Medical and Diagnostic Center
    Kropyvnytskyi, 25006, Ukraine
  • Medical centre "Verum" Limited Liability Company
    Kyiv, 03039, Ukraine
  • Vita Сom LLC
    Kyiv, 03141, Ukraine
  • The State Institution "Romodanov Neurosurgery Institute,
    Kyiv, 04050, Ukraine
  • Llc Medical Centre
    Odesa, 65006, Ukraine
  • Municipal Non-profit Enterprise Odesa Regional Clinical Hospital of Odesa Regional Council
    Odesa, 65025, Ukraine
  • Llc Lidermed
    Odesa, 65062, Ukraine
  • Municipal Non Profit enterprise of Sumy Regional Council "Sumy Regional Clinical Oncology Center"
    Sumy, 40022, Ukraine
  • Llc Medical Center Diamed
    Uzhhorod, 88000, Ukraine
  • MNPE Central City Clinical Hospital of Uzhhorod City Council
    Uzhhorod, 88000, Ukraine
  • Мunicipal non-profit enterprise "Zhytomyr Regional Oncology Dispensary" of Zhytomyr Regional Council
    Zhytomyr, 10002, Ukraine
09

References and documents

Publications

  • Penkov K, Bondarenko I, Saenko DV, Kulyaba Y, Guo J, Gong Y, Yamamoto N, Hotko YS, Boyko V, Fadeeva NV, Ursol GM, Ahn HK, Kislov NV, Shen CI, Davis C, Kowalski K, Michelon E, Pavlov D, Hirohashi T, Cho BC. Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies. Ther Adv Med Oncol. 2024 Sep 11;16:17588359241274592. doi: 10.1177/17588359241274592. eCollection 2024. PubMed 39281971 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Mar 2022, 23 months.

Results were first posted in May 2023, 1 year 2 months after primary completion.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's 23 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2019
First posted
Nov 29, 2019
StartActual
Mar 18, 2020
Primary completionActual
Mar 3, 2022
CompletionActual
May 13, 2026
Results first posted
May 8, 2023
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04181788
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 29, 2019
Start date
Mar 18, 2020
Primary completion
Mar 3, 2022
Completion
May 13, 2026
Results posted
May 8, 2023
Last update
Jun 15, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sasanlimab

Start the discussion